Epigenetic drug LSD1 inhibitor, which can activate CTAs, may boost the immunogenicity of tumour cells and further enhance the therapeutic effects of immune-checkpoint inhibitors in the clinic. The gene discussed is KDM1A; the disease is neoplasm.